Late Discovery & Investigative Research

NGT BioPharma Consultants understands the challenges companies face when selecting a clinical candidate to advance into preclinical development. To increase the efficiency and effectiveness of this process, we work collaboratively with our clients to provide a clear assessment of an asset’s attributes, including risks, to ensure critical experiments are prioritized. We can then provide a comprehensive plan to navigate the many interdependent preclinical activities, expediting your asset’s path into the clinic.

We leverage our collective expertise and extensive experience to generate fit-for-purpose progression plans and provide this consultancy in close alignment with the expertise of NGT consultants experienced in Nonclinical Sciences, CMC, Regulatory and Quality/Compliance disciplines.

Although NGT is neither a laboratory or manufacturing services provider, we can serve as your single point of contact to our network of reputable CROs and CDMOs.

Screen Shot 2022-06-20 at 7.14.10 PM

For more information please contact:

Michael Neeb


Rachel Franckowiak

Senior Director, Administration